Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP - Get Free Report) shares crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.48 and traded as low as $0.48. Elite Pharmaceuticals shares last traded at $0.48, with a volume of 438,479 shares traded.
Elite Pharmaceuticals Trading Down 0.8 %
The firm has a market cap of $512.81 million, a price-to-earnings ratio of -24.00 and a beta of 0.14. The business has a 50 day moving average of $0.50 and a 200 day moving average of $0.49. The company has a quick ratio of 1.90, a current ratio of 3.27 and a debt-to-equity ratio of 0.12.
Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last released its earnings results on Thursday, February 13th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter. Elite Pharmaceuticals had a negative return on equity of 6.92% and a negative net margin of 25.70%.
About Elite Pharmaceuticals
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
See Also
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
